Company / EPS (Basic)
Xenon Pharmaceuticals Inc. EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$4.36
FY2025
5-year range
-$4.36 / -$1.77
FY2021-FY2025
Trend
-44.9%
vs FY2024
Sector context
#171 of 208
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s eps (basic) of $-4.36 is lower than 82% of companies in the Health Care sector (FY2025). EPS (Basic) has declined for 5 consecutive years, from $-0.81 in FY2020 to $-4.36 in FY2025.
Based on SEC 10-K filings.
-4.36 in FY2025.
Declined from $-2.73 to $-4.36 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 208This company -$4.36 Sector average -$0.87
▼
-400.8% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s eps (basic) has declined for 5 consecutive years.
- In FY2025, eps (basic) decreased 44.9% year-over-year.
- Ranks #171 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.36 | -44.9% |
| FY2024 | -$3.01 | -10.3% |
| FY2023 | -$2.73 | -32.5% |
| FY2022 | -$2.06 | -16.4% |
| FY2021 | -$1.77 | -118.5% |
| FY2020 | -$0.81 | - |
| FY2019 | - | - |
| FY2018 | -$1.71 | -55.5% |
| FY2017 | -$1.10 | -126.8% |
| FY2016 | $4.11 | +43.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026